Congratulations to an amazing scientist and friend Kaechlab (Sue Kaech) for her election to the National Academy of Sciences!

LCRF announces its 9/24 Evening of Innovation gala honoree, Dr. Mark G. Kris of Memorial Sloan Kettering Cancer Center. Dr. Kris exemplifies the spirit of LCRF to improve the lives of those with #LungCancer through research. Read about this tireless visionary & advocate: LCRF.org/gala-article

Exciting partnership and amazing opportunity!

Online Now: Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation dlvr.it/SzBGr0

If you’re interested in the Pharmacology Ph.D. Program and TMMPP at Yale, join us Monday for an applicants info session.

Applying to Yale's BBS PhD Program? Register for one of two virtual info sessions hosted by TMMPP faculty!

Monday, October 23rd 7:00 – 7:45 PM EST
yale.zoom.us/meeting/regist…

Monday, October 30th 10:00 – 10:45 AM EST
yale.zoom.us/meeting/regist…

Yale School of Medicine Yale West Campus Yale Pharmacology

Very excited to be riding with this fantastic team of 'Oncogenic Riders' for cancer research in the Closer to Free Closer To Free Ride rideclosertofree.org/index.cfm?fuse…
Yale Cancer Center

#patientadvocacy does work!!! This is the news and ⁦CMSGov⁩ heard our voices. We are grateful. S-codes for #DIEPflap #BreastReconstruction will NOT sunset and will be maintained. Thank you EVERYONE! Far too many to tag or mention. 🌸💕 #breastcancer #bcsm

Amazing news!

Fantastic team!

Please help us enroll in this Susan G. Komen Advocacy funded registry study on oligo metastatic Her2 pos study #bcsm Yale Cancer Center YaleBreastCancer

Check it out: ascopubs.org/doi/abs/10.120…

Great paper from Rohit Thummalapalli and Kathryn C. Arbour from MSK Department of Medicine Memorial Sloan Kettering Cancer Center Shows a couple of key findings for patients with KRAS G12C mutated NSCLC treated with sotorasib. ascopubs.org/doi/abs/10.120… JCO Precision Oncology

Sharing this piece that I wrote on a topic that hits close to home for me-reconstruction after breast cancer surgery. ⁦Yale Cancer Center⁩ thehill.com/opinion/health…

Roy Herbst smiled at the history-making results of ADAURA #ASCO23 Plenary. The 1st demonstration of OS benefit to adj EGFR TKIs. To me, this is clinically meaningful & practice changing. Now we have to learn how to tell who is at risk for this disease and SCREEN them!

ADAURA trial of adjuvant osimertinib in egfrm early stage NSCLC shows 12% overall survival benefit consistent across all subgroups and independent of prior adjuvant chemotherapy use - fabulous news for patients with egfrm early stage lung cancer 👏 Roy Herbst and colleagues